Is drotrecogin alfa used in the treatment of bacterial pneumonia?

Updated: Sep 30, 2020
  • Author: Justina Gamache, MD; Chief Editor: Guy W Soo Hoo, MD, MPH  more...
  • Print
Answer

A recombinant version of human activated protein C, drotrecogin alfa (Xigris), was withdrawn from the worldwide market in 2011 after it failed to demonstrate a statistically significant reduction in 28-day all-cause mortality in patients with severe sepsis and septic shock.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!